Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C1QTNF3-AMACR readthrough (C1QTNF3-AMACR)
- Target
- C1QTNF3-AMACR
- Molecular classification
- Other (readthrough/lncRNA candidate, not a protein-coding receptor, enzyme, transporter, etc.)
01
Overview
C1QTNF3-AMACR readthrough is a naturally occurring chimeric RNA transcript that includes sequences from the adjacent C1q and tumor necrosis factor related protein 3 (C1QTNF3) and alpha-methylacyl-CoA racemase (AMACR) genes on chromosome 5. This transcript is a candidate for nonsense-mediated mRNA decay (NMD) and does not produce a functional protein product. It is typically classified as a long non-coding RNA (lncRNA), not a functional receptor, enzyme, transporter, or therapeutic target. The existence of this RNA transcript likely reflects transcriptional readthrough rather than a biologically relevant molecular entity with independent function. This entry is not considered a valid drug target as it is not known to have a function or encode a druggable protein. If your interest is in AMACR or C1QTNF3, these should be addressed as separate molecular entities.
- Other names
- C1QTNF3-AMACR readthrough (NMD candidate)C1QTNF3/AMACRC1QTNF3-AMACR RNA
02
Mechanism of action
None
03
Biological functions
None directly; this locus does not encode a functional protein, but the parental genes (C1QTNF3 and AMACR) are involved in metabolic and regulatory functions
04
Disease associations
None directly for the readthrough; parental genes involved in some diseases (e.g., AMACR in metabolic defects and prostate cancer)
05
Biomarkers
None specific for this readthrough product
Beyond the preview
Go deeper on C1QTNF3-AMACR readthrough (C1QTNF3-AMACR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C1QTNF3-AMACR readthrough (C1QTNF3-AMACR).